Blockchain Registration Transaction Record

Quantum BioPharma Advances Phase 2 MS Trial with Thermo Fisher Partnership

Quantum BioPharma partners with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a novel multiple sclerosis treatment targeting PAD2 to prevent myelin degradation.

This news matters because it signals tangible progress in developing a novel treatment for progressive multiple sclerosis, a debilitating disease with few effective therapies. By targeting PAD2 to prevent myelin degradation, Lucid-MS offers a potentially first-in-class approach that could not only slow but possibly reverse MS progression. The partnership with Thermo Fisher's PPD clinical research business brings world-class expertise to the trial, increasing the likelihood of successful execution. For the estimated 2.8 million people worldwide living with MS, this trial represents a beacon of hope for a better future. Investors in Quantum BioPharma also have reason to be optimistic, as a successful trial could unlock significant value and validate the company's innovative pipeline.